Fig. 6

Schematic diagram showing the amino acid sequence of CB5005 (A), the NF-κB pathway and the approach for CB5005 to penetrate cell membrane and translocate into cell nucleus (B). Permeability analyses on U87 tumor spheroids after incubation for 4 h with CB5005-FAM, CB5005M-FAM, CB5005N-FAM and FAM under a concentration of 5 μM. Fluorescence images were multi-level scans of the tumor spheroids, and the interval between consecutive slides was 5 μm (C). Reprinted with permission from ref. [155] Copyright (2016) Elsevier. Size distribution of LS/DOX and CB5005-LS/DOX (D). In vivo distribution and antitumor effects of liposomes in intracranial glioblastoma-bearing nude mice. E The in vivo distribution of CB5005-LS/DiR and LS/DiR in intracranial glioblastoma-bearing nude mice (a) and the ex vivo distribution in brains (b), intracranial glioblastoma (c) and other organs (top to bottom were heart, liver, spleen, lung and kidney) (d). From left to right, the mice were treated with CB5005-LS/DiR, LS/DiR and normal saline, respectively. The formulations were injected via caudal vein at a dose of 100 μL with a concentration of 0.01 μM DiR. Dissected tissues, brain and intracranial glioblastoma were immediately observed at 4 h post injection. Fluorescence intensity in intracranial glioblastoma. Data were presented as mean ± SD (n = 3) (F). Kaplan–Meier survival curves of nude mice bearing intracranial glioblastoma (G). (Asterisk) Denotes statistical significance, **p < .01, and ***p < .001. Reprinted with permission from ref. [156]. Copyright (2018) Elsevier